 |
|
 |
 |
 |
|
|
DIADEXUS APPOINTS TWO NEW MEMBERS TO ITS BOARD OF DIRECTORS Santa Clara, CA - June 19, 2001 - diaDexus today announced the appointment of Gregory B. Abbott, Esq. and Jon S. Saxe, Esq. to its board of directors. Mr. Abbott is the managing partner of the Seattle office of Cooley Godward LLP, focusing on emerging growth companies in the life science and information technology industries. Previously, Mr. Abbott served as chief executive officer at three biotechnology companies: Synergen, acquired by Amgen, Inc.; Darwin Molecular, acquired by Chiroscience plc and AlphaGene, Inc. Prior to joining the biotechnology industry, Mr. Abbott was a partner with Holme Roberts & Owen, where he practiced corporate and securities law and led the firm's technology practice group. Mr. Abbott received his B.A. from Yale University and his J.D. from the University of Denver College of Law. A biotechnology veteran, Mr. Saxe currently serves as a director on the boards of numerous companies including: Protein Design Labs; Questcor Pharmaceuticals, Inc.; Incyte Genomics, Inc.; ID Biomedical Corporation; InSite Vision; First Horizon Pharmaceutical Corporation and Arbor Vita Corporation. In addition, he is chairman of POINT Biomedical Corporation, Iconix Pharmaceuticals and VistaGen, Inc. Mr. Saxe has served as president of Protein Design Labs and Saxe Associates; president, chief executive officer and director at Synergen, Inc. and vice president of licensing & corporate development and head of patent law for Hoffmann-La Roche. Mr. Saxe received his B.S. in chemistry from Carnegie-Mellon University, his J.D. from George Washington University School of Law and his L.L.M from New York University School of Law. Mr. Saxe takes Dr. Randy Scott's place on the diaDexus board. Dr. Scott stepped down to focus his attention upon his new company, Genomic Health, Inc. "We are pleased to welcome such experienced biotechnology executives to our board of directors. We are also very grateful to Dr. Scott for his significant contributions to diaDexus since its formation in 1997 and wish him every success in his new endeavor," said Patrick Plewman, chief executive officer of diaDexus, Inc. diaDexus, located in Santa Clara, California, is focused on translating genomic sequence data into novel diagnostic and therapeutic products. diaDexus has utilized genomics and bioinformatics to identify thousands of disease-associated molecular targets. Currently, diaDexus has two diagnostic product candidates in late-stage pre-clinical development. For more information, please visit the diaDexus Web site at www.diadexus.com. |
|
|
|
